2023 World Conference on Lung Cancer (Posters)-EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases

EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference analyzed the clinical outcomes of patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) who received immunotherapy combined with whole brain radiotherapy (WBRT). The study aimed to determine the optimal timing of this combined therapy. <br /><br />The study retrospectively analyzed 257 patients with driver-gene-negative NSCLC-BMs and stable extracranial control. The patients were divided into two groups: those who received immune checkpoint inhibitors (ICIs) plus WBRT and chemotherapy, and those who received WBRT alone with chemotherapy. The primary endpoints were intracranial progression-free survival (iPFS) and intracranial response, while secondary endpoints included progression-free survival (PFS) and overall survival (OS). <br /><br />The results showed that patients treated with ICIs plus WBRT had better survival benefits compared to those treated with WBRT alone. Within the ICIs plus WBRT group, patients who received concurrent therapy or ICIs after WBRT had longer median iPFS, PFS, and OS compared to those who received ICIs before WBRT. <br /><br />Furthermore, adding ICIs to WBRT as soon as possible (within 2 weeks) significantly enhanced intracranial control. However, an interval longer than 2 months between ICIs and WBRT was associated with a decrease in intracranial control and survival. <br /><br />In conclusion, the addition of immunotherapy to WBRT may improve survival outcomes in NSCLC patients with BMs. Performing immunotherapy concurrently with WBRT or after WBRT results in better survival and intracranial control. Starting immunotherapy within 2 weeks of WBRT enhances intracranial control, while a longer interval between ICIs and WBRT negatively impacts outcomes.

Asset Subtitle

Shilan Luo

Meta Tag

Speaker Shilan Luo

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

WCLC 2023 conference

non-small cell lung cancer

brain metastases

immunotherapy

whole brain radiotherapy

optimal timing

intracranial progression-free survival

progression-free survival

overall survival

intracranial control